Effectiveness of mesenchymal stem cells for treating patients with knee osteoarthritis: a meta-analysis toward the establishment of effective regenerative rehabilitation.
Hirotaka Iijima,Hirotaka Iijima,Hirotaka Iijima,Takuya Isho,Hiroshi Kuroki,Masaki Takahashi,Tomoki Aoyama +6 more
TLDR
It is suggested that more high quality randomized controlled trials with consideration of the potential rehabilitation-driven clinical benefit would be needed to facilitate the foundation of effective MSC treatment and regenerative rehabilitation for patients with knee OA.Abstract:
This systematic review with a meta-analysis aimed to summarize the current evidence of the effectiveness of mesenchymal stem cell (MSC) treatment for knee osteoarthritis (OA) and to examine whether rehabilitation is an effect modifier of the effect estimate of MSC treatment. A literature search yielded 659 studies, of which 35 studies met the inclusion criteria (n = 2385 patients; mean age: 36.0–74.5 years). The meta-analysis results suggested that MSC treatment through intra-articular injection or arthroscopic implantation significantly improved knee pain (standardized mean difference [SMD]: −1.45, 95% confidence interval [CI]: −1.94, −0.96), self-reported physical function (SMD: 1.50, 95% CI: 1.09, 1.92), and cartilage quality (SMD: −1.99; 95% CI: −3.51, −0.47). However, the MSC treatment efficacy on cartilage volume was limited (SMD: 0.49; 95% CI: −0.19, 1.16). Minor adverse events (knee pain or swelling) were reported with a wide-ranging prevalence of 2–60%; however, no severe adverse events occurred. The evidence for these outcomes was “very low” to “low” according to the Grades of Recommendation, Assessment, Development and Evaluation system because of the poor study design, high risk of bias, large heterogeneity, and wide 95% CI of the effects estimate. Performing rehabilitation was significantly associated with better SMD for self-reported physical function (regression coefficient: 0.881, 95% CI: 0.049, 1.712; P = 0.039). We suggest that more high quality randomized controlled trials with consideration of the potential rehabilitation-driven clinical benefit would be needed to facilitate the foundation of effective MSC treatment and regenerative rehabilitation for patients with knee OA.read more
Citations
More filters
Journal ArticleDOI
Recent Updates of Diagnosis, Pathophysiology, and Treatment on Osteoarthritis of the Knee.
TL;DR: In this paper, the contents of non-cellular and cellular therapies for OA, and briefly summarized the results of clinical trials for cell-based OA therapy to lay a solid application basis for clinical research.
Journal ArticleDOI
An Update on the Progress of Isolation, Culture, Storage, and Clinical Application of Human Bone Marrow Mesenchymal Stem/Stromal Cells.
Dinh-Toi Chu,Dinh-Toi Chu,Thuy Nguyen Thi Phuong,Nguyen Le Bao Tien,Dang-Khoa Tran,Vo Van Thanh,Thuy Luu Quang,Dang Tien Truong,Van Huy Pham,Vo Truong Nhu Ngoc,Thien Chu-Dinh,Kushi Kushekhar +11 more
TL;DR: This review highlights and updates on the progress of production, as well as provides further challenges in the studies of BMSCs, for the approval of B MSCs widely in clinical application.
Journal ArticleDOI
Inflammatory priming enhances mesenchymal stromal cell secretome potential as a clinical product for regenerative medicine approaches through secreted factors and EV-miRNAs: the example of joint disease
Enrico Ragni,Carlotta Perucca Orfei,Paola De Luca,Carlotta Mondadori,Marco Viganò,Alessandra Colombini,Laura de Girolamo +6 more
TL;DR: To deeply characterize adipose-derived MSC (ASC)-secreted factors and EV-miRNAs, and their modulation after IFNγ preconditioning, ASC secretome showed a marked capacity to stimulate cell motility and modulate inflammatory and degenerative processes.
Journal ArticleDOI
Mesenchymal stem cells in knee osteoarthritis treatment: A systematic review and meta-analysis.
TL;DR: It is suggested that MSC therapy could serve as an effective and safe therapy for clinical application in OA treatment and have great translational potential in the clinical treatment of various degenerative diseases once optimum formula and explicit target population are identified.
References
More filters
Journal ArticleDOI
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
TL;DR: Moher et al. as mentioned in this paper introduce PRISMA, an update of the QUOROM guidelines for reporting systematic reviews and meta-analyses, which is used in this paper.
Journal Article
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
TL;DR: The QUOROM Statement (QUality Of Reporting Of Meta-analyses) as mentioned in this paper was developed to address the suboptimal reporting of systematic reviews and meta-analysis of randomized controlled trials.
Journal ArticleDOI
Measuring inconsistency in meta-analyses
TL;DR: A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.
Journal ArticleDOI
A power primer.
TL;DR: A convenient, although not comprehensive, presentation of required sample sizes is providedHere the sample sizes necessary for .80 power to detect effects at these levels are tabled for eight standard statistical tests.
Journal ArticleDOI
Bias in meta-analysis detected by a simple, graphical test
TL;DR: Funnel plots, plots of the trials' effect estimates against sample size, are skewed and asymmetrical in the presence of publication bias and other biases Funnel plot asymmetry, measured by regression analysis, predicts discordance of results when meta-analyses are compared with single large trials.
Related Papers (5)
Adipose Mesenchymal Stromal Cell-Based Therapy for Severe Osteoarthritis of the Knee: A Phase I Dose-Escalation Trial
Yves-Marie Pers,Lars Rackwitz,Rosanna Ferreira,Oliver Pullig,Christophe Delfour,Frank Barry,Luc Sensebé,Louis Casteilla,Sandrine Fleury,Philippe Bourin,Danièle Noël,François Canovas,C. Cyteval,Gina Lisignoli,Joachim H. X. Schrauth,Daniel Haddad,Sophie Domergue,Ulrich Noeth,Christian Jorgensen +18 more